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Abstract 
 In critical care tight control of blood glucose levels has been shown to lead to 
better clinical outcomes. The need to develop new protocols for tight glucose control, as 
well as the opportunity to optimize a variety of other drug therapies, has led to a 
resurgence in model-based medical decision support in this area. One still valid hindrance 
to developing new model-based protocols using so-called virtual patients, retrospective 
clinical data, and Monte Carlo methods is the large amount of computational time and 
resources needed.  
 
This paper develops fast analytical-based methods for an insulin-glucose system model 
that are generalizable to other similar systems. Exploiting the structure and partial 
solutions in a subset of the model is the key in finding accurate fast solutions to the full 
model. This approach successfully reduced computing time by factors of 5600-144000 
depending on the numerical error management method, for large (50-164 patient) virtual 
trials and Monte Carlo analysis. It thus allows new model-based or model-derived 
protocols to be rapidly developed via extensive simulation. The new method is rigorously 
compared to existing standard numerical solutions and is found to be highly accurate to 
within 0.2%.  
 
 
Keywords: Model-based therapeutics; fast simulation; blood glucose control; Monte 
Carlo analysis; analytical solutions; computation 
 
1 Introduction 
 
Fast and efficient computational methods are important for real-time therapy guidance 
and are a growing trend in Bio-Engineering [1-11]. More recently, significant clinical 
outcomes have been achieved by table-based glucose control protocols [12-14] that 
mimic and are developed from computer-based protocols [15-18], but are much simpler 
to implement and more likely to be accepted by clinical staff [19]. Such model-derived or 
model-validated approaches are also increasing in prevalence [20, 21].  
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Tight control of blood glucose levels gained significant importance in critical care after 
Van den Berghe et al. [22] showed reductions in mortality rates of up to 45% are 
possible. The common way of assessing risk of death in the ICU is by an APACHE score, 
which measures the severity of illness. Thus, higher scores mean a higher risk of death. 
The trials in [12-14] represent the first model-based or model-derived protocol to report a 
significant clinical outcome with a 32% mortality reduction [18], despite significantly 
high APACHE scores. This trial also had some of the tightest glucose control reported as 
compared to other studies e.g. [2, 18, 23-29], indicating the potential of computational 
models to impact this field.  
 
A major component in the development of these model-based protocols [13, 14, 18] is the 
concept of “virtual patient trials” where each new potential protocol is tested in 
simulation off-line, with up to hundreds of thousands of patient hours [12, 21]. This 
approach can include Monte Carlo analysis methods, which can add the effects of 
parameter uncertainty and different sensor errors into the analysis [16, 30]. The major 
advantage of a “virtual patient” approach is that algorithms and methods can be tested 
and optimized safely before clinical implementation. Furthermore, the approach gives 
insight into potential long term clinical performance and provides a repeatable cohort for 
easy comparison of different protocols [12, 13]. The considerable patient variation and 
sensor noise combined with different variations in the glucose-insulin physiological 
modelling can lead to large numbers of simulations required. Thus, a fundamental 
requirement in this “model-based therapeutics” approach is very fast and accurate 
simulation methods that can be performed using simple programme languages, such as 
Matlab, to minimize development time. 
 
A virtual patient database represents a summary of the metabolic changes and 
interventions for patients in a given cohort over the entire length of stay in the intensive 
care unit (ICU). The primary parameter used to represent patients’ metabolic status [12, 
13] was insulin sensitivity ( IS ), which was allowed to vary with time but was held 
constant over each one hour period. These IS  profiles were established from 
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retrospective clinical data using an integral-based parameter identification method [20]. 
Data from patients in other trials [15-18] was also added to this database.  
 
The process of creating a virtual patient cohort and then testing or creating new protocols 
using the physiological model is referred to here as “model-based therapeutics” (MBT). 
This MBT approach led to the development of the Specialized Relative Insulin + 
Nutrition Tables (SPRINT) protocol that has been implemented in the Christchurch 
Hospital ICU [12-14, 18, 31]. Successful initial results have also been obtained in several 
other areas, including model based cardiac diagnosis [32-36], sedative drug delivery [37, 
38] and insulin sensitivity measurement [30, 39]. 
 
In all these cases, extensive simulation (Monte Carlo based) is performed in virtual trials 
to ensure robustness of the protocols developed. Some analyses run as many as 100,000-
200,000 patient hours (80-160 patient years) in total [13, 14]. Thus, a fundamental 
element in the MBT approach must be highly accurate, easily programmable, very fast 
forward solutions to non-linear physiological models to reduce computational burden and 
run-time. 
 
To get an idea of the computation time required, the original MATLAB simulation code 
used to develop the SPRINT system [13, 14], which originally used 19 patients, takes 0.9 
seconds to simulate one patient hour on a PC with a 2.4GHz processor and 2GB RAM. 
This simulation uses a maximum step size of 0.019 based on an error analysis to ensure 
the 90th percentile error is less than 0.1%. Note that using an error analysis based on 
reducing the relative error tolerance instead of the maximum step size, would yield faster 
results of 0.035 s for one patient hour. However, for highly stiff systems (e.g. [36]), the 
maximum step size method was found to be a more reliable and conservative option, so 
was used in the development of SPRINT. In this case, the Monte Carlo (100x) testing of a 
new protocol on 384 patients (42,000 hours) would require 4,200,000 patient hours ×  
0.9s = 43.8 days of simulation. As more patients are added, greater numbers of protocols 
are tested, and potentially more dynamics are added to the glucose-insulin model (e.g. a 
more detailed carbohydrate input model), then even more significant computing time and 
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resources would be required. Thus, the computational time would significantly
 
 limit the 
number of patients and protocols that could be tested, potentially hindering research and 
clinical outcomes. 
The glucose control protocols discussed [2, 12-17, 40, 41] require a simulated 
measurement only 1-2 hourly. In contrast, to obtain sufficient accuracy, numerical ODE 
solvers (e.g. [16]) compute the glucose value at every time step (minutes or seconds) 
throughout an hour. In other words, a large percentage of computation is spent calculating 
glucose values that are not used in a virtual trial or clinical control. However, the 
reasonably typical non-linear glucose-insulin model [17] has no direct analytical solution. 
Furthermore, other insulin-glucose models reported in the literature, ranging from 
relatively simple e.g. [42], to far more complicated [43], also require computationally 
intense  numerical solutions. Hence, the computational cost of extensive virtual trials 
simulations yields values that are necessary only for accurate solution by the solver, but 
are not used directly in protocol development. 
 
The approach in this research, is to form partial analytical solutions to a subset of the 
model in terms of simpler approximating functions that are valid within known 
physiological bounds. These simpler functions then enable an analytical solution to the 
whole model to be constructed. More specifically, the approach is to reformulate and 
tailor solutions to the specific application required. With careful construction and the use 
of known mathematical solutions to differential equations, it is shown that an 
approximate, but highly accurate, analytical solution can be found to the full non-linear 
glucose-insulin system model. This solution dramatically increases the forward 
simulation speed of the model, by avoiding the need to calculate values that are not used 
in the virtual trial simulations. It thus enables far more rapid development of new 
protocols using the virtual patient based MBT approach.  
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2 Methodology 
 
2.1 Model of glucose and insulin kinetics 
 
The model of glucose and insulin kinetics [17] used to run virtual trials in this research 
originates from Bergman’s minimal model [42]. Additional non-linear terms, a more 
physiologically representative formulation, and time varying insulin 
sensitivity, ( )tS=S II , creates the system model defined [2, 12-17, 40]: 
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= − − + +
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 Q kQ k= − + Ι                                                                     (2) 
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where eqG  is the equilibrium plasma glucose concentration and G  is the plasma glucose 
concentration above eqG . The exogenous feed input rate is denoted ( )tP ; ( )tI  is the 
plasma insulin resulting from exogenous insulin input ( )tuex ; ( )tQ  is the concentration of 
insulin bounded to interstitial sites; k accounts for the effective life of insulin in the 
system. Patient endogenous glucose clearance and insulin sensitivity are Gp  and IS  
respectively; V  is the insulin distribution volume and n  is the constant first order decay 
rate for insulin from plasma. Michaelis-Menten functions are used to model saturation, 
with Iα  used for the saturation of insulin disappearance, and Gα  for the saturation of 
insulin-dependent glucose clearance; prk  and pdk  are the decay constants for increasing 
and decreasing feed rates where iP  and 1+iP  are the steps in enteral glucose feed rates. 
Thus, Equation (4) is essentially the analytical solution to the 2 compartment system in 
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[16, 17]. Note that ( )tP  is defined as mmol/L/min, accounting for the glucose distribution 
volume. 
  
The parameters ( 2 L1V = , 10.16 minn −= , 10.01 mink −= , 0.04 L/mUGα = , 
0.0017 L/mUIα = ,
10.01 minGp
−= ) are average values found from an extensive 
literature search and eqG  is estimated from the moving mean glucose concentration 
during a patient’s stay [17, 20]. The parameter SI  is patient specific. Note that for 
simplicity, the model is reformulated by replacing G by Gtotal - Geq in Equation (1): 
 
 ( ) ( )1total G total eq I total G
Qp G G
Q
G G S P t
α
= − − − +
+
                     (5) 
 
 
2.2 Virtual patient cohort 
 
For this research, 17 uncontrolled patients from the study in [20] and 51 controlled 
patients in the original pilot study of the SPRINT system [13, 14] were used to form the 
virtual patient cohort. Each patient’s physiology was summarized by their insulin 
sensitivity profile ( )tSI , which was obtained using the integral based parameter 
identification method of [20] and the retrospective data.  
 
Given new nutritional and insulin inputs, the virtual patient’s ( )tSI  profile can be used in 
Equations (2)-(5) to generate a (new) set of glucose levels for these different 
interventions, which is referred to as a “virtual trial” [12, 44]. Different protocols can 
then be applied on a specific patient by changing the nutritional and insulin inputs for the 
identified ( )tSI  profiles. Thus, potential improvements to a current retrospective protocol 
can be tested without requiring a full clinical trial. Therefore, for any new clinical trial, a 
protocol could be shown to be ‘safe’ and robust, as well as being optimized for the best 
possible clinical outcomes. 
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2.3 Analytical solution to insulin I(t) without saturation 
 
In the ICU, for a given hour, the exogenous insulin input uex(t) in Equation (3) is a 
combination of a bolus and infusion and is defined: 
 
( ) , 0 1
, 1 60
be ix
i
u t u u t
u t
≤ ≤
= < ≤
= +
     (6) 
 
If the saturation parameter αI is set to 0, Equation (3) has an analytical solution: 
 
0( ) ( ),
( ), 1
0
60
1
i
bII t I t t
I t t
α = = ≤
= ≤ ≤
≤
     (7) 
( 1)( ) ( ) , 1 61 0n ti ibi
U UI t e I
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  (8) 
( )01( ) ( )ntb b i b it u u e nI u u In
−= + − + −    (9) 
 
 
The solution in Equations (7)-(9) will serve as an initial approximation to the solution of 
Equation (3) with 0Iα ≠ . 
 
2.4  Iterative analytical solution I(t) with saturation 
 
For a given approximation, Iapprox(t) to I(t), Equation (3) can be approximated by: 
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( ) ( )extI t I u t= α +      (10) 
)(1
)(
tI
nt
approxIα
α
+
=                     (11) 
 
where α(t) is a known function of time. However, Equation (10) does not have a closed 
form analytical solution for any form of ( )approx tI . Thus, the approach is to approximate 
α(t) in Equation (11) by an integrable function, then Equation (10) can be solved by the 
integrating factor. 
 
2.4.1 Insulin solution in the first minute 
 
In the first minute, Iapprox(t) in Equation (11) is replaced by Ib(t) of Equation (9), which 
yields: 
)(1
)(
tI
nt
bI
b α
α
+
=      (12) 
The integrating factor of Equation (10) with ( ) ( )bt tα = α from Equation (12) is defined: 
 
in ( )t( ) bb
tt e αµ =      (13) 
int ( ) ( )t bob t dα = α τ τ∫          (14) 
 
The analytical solution to Equation (10) in the first minute is thus: 
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, 0 0( ) ( )
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b
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− − τα α α= + + τ∫   (15) 
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There is no closed form solution to the integral in Equation (14), therefore a piecewise 
linear approximation to int ( )b tα in Equation (14) over t=0,0.5,1 is defined: 
1
2 2
10int (
2
, 1
,
1
)
2
b t b t
a b t t
tα ≤ ≤
= + < ≤
=
      (16) 
( )1 2 12 int 2 int int (1), 2 int 1 int
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      −            
  (17) 
where from the trapezium rule: 
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
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 
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Using Equation (16) to approximate ( )int b tα , closed form expressions for the solution of 
Equation (15) at 1
2
t =  and 1t = are defined: 
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1
2
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b
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 
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where a2, b1 and b2 are defined in Equation (17). 
 
2.4.2 Insulin solution after first minute 
 
After the first minute, Iapprox(t) in Equation (11) is replaced by 0( )II tα =  in Equation (7), 
which yields: 
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0
1( 6) 0,
1 ( )I
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α
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To enable Equation (22) to be integrated analytically αi(t) is approximated by the 
function: 
 
2
0 1 2 3( ) ( )
nt
i t a a a t a t e
−= + + +α       (23) 
( 1) ( 1) 2 ( 1)
1 2 3(1) ( 1) ( 1) ( 1)
n t n t n t
i A e A t e A t e
− − − − − −= α + − + − + −     (24) 
0 1 1 1 2 3 2 2 3 3 3(1) , ( ) , ( 2 ) , 2
n n n
ia A a A A A e a A A e a A e= α − = − + = − =  (25) 
 
where Equation (24) is an equivalent form of Equation (23) that satisfies (1) (1)i iα = α . 
Note that the form of Equations (23) and (24) is motivated from the analytical solution of 
Equation (8) with two extra polynomial terms added to account for saturation. The 
approximation also settles at an equilibrium value as t →∞ , which matches the expected 
physiology. This approach follows the general philosophy presented in this paper which 
is to generate approximations that are valid within known physiological constraints and 
behaviour. Substituting three values of 321 ,, tttt = into Equation (24) yields a matrix 
equation: 
 
11 12 13 1 1
21 22 23 2 2
31 32 33 3 3
A b
A b
A b
β β β    
    β β β =    
    β β β    
   (26) 
where: 
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( 1) ( 1) ( 1)2
1 2 31, ( 1) , (
( ) (1), 1 3
1
,
)
,
,n t
j i
n t n tj j j
j j j j
i
j
j
e e
j
t
t
e
b
t− − − − − −
= α − α =
β = − β = − β = −
…
(27) 
 
Since the insulin response is evaluated over 60 minutes, 3 60t = . The values of t1 and t2 
need to be chosen carefully to take into account different insulin clearance rates n, and 
this process is explained in a later section. Equation (26) can be solved analytically for 
A1, A2 and A3 in Maple which yields: 
 
 
1 1 2 2 3 3 21 1 3 3 11 2 23 3
3 2
3
( ) ( ),
det
b b b
b
C b C b C b b A b AA A
C
+ + −β −β +β −β
= =
β
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11 12 13
1 12 2 13 3
1 21 22 23
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31 32 33
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−β −β  = β = β β β β  β β β 
  (29) 
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β β β β β β     
= = − =     β β β β β β    
 (30) 
 
where A2 and A1 are defined recursively to minimise computation. Once A1, A2 and A3 are 
known, a0,…,a3 are determined from Equation (25). Hence the integrating factor of 
Equation (10) with ( ) ( )it tα = α  in Equation (22) is approximated by: 
in ( )t( )i
tit e αµ =        (31) 
3
2
0 1 21
1 1
int ( ) ( )
int ( ) int (1)
t nt nt nt
i t a a e a te a t e dt
t
− − −
α = + + +∫
= −
       (32) 
1 2 2 3 3
1 2 3
1 0 1
2 2
2 3
( ) (int ( )
1 1 1, ( 1) , ( 2
) ( )
( ) ) )( ) 2(nt nt nt
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e nt e
t a t a t a
t n t nt t e
n n n
t− − −
φ φ φ
φ = φ = φ
= + +
+=
+
− − + +
 (33) 
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The next step is to approximate ( )i tµ  in Equation (31) by: 
31 2
0 1 2 3( )
D tD t D t
i t B B e B e B e= + + +µ      (34) 
( 1)( 1) ( 1) 31 2
1 2 31 ( 1) ( 1) ( 1)
D tD t D tC e C e C e −− −= + − + − + −              (35) 
2 31
1 2 3
1 2 3
int ( ) int ( )int ( )
, ,i i i
t tt
D
t t
D
t
Dα α α= = =    (36) 
31 2
0 0 1 2 3 1 1 2 2 3 3, , ,
DD DB C C C C B C e B C e B C e−− −= − − − = = =   (37) 
The motivation for the form of Equation (34) comes from the fact that, when t=tk, in 
Equation (34) the kth exponential term D tke  becomes int ( ) ( )tki i ke t
α = µ . Hence, each basis 
function D tke behaves like the true solution in a neighbourhood surrounding each point 
kt t= , where k=1,…,3. the sum in Equation (34) ensures the solution is accurate between 
the points kt t= . Note that a cubic could have potentially been used instead of the sum of 
exponentials in Equation (34) however it was found to be a very poor interpolant between 
the kt  time points. 
 
Substituting t=t1,t2,t3 into Equation (35) yields a matrix equation: 
 
11 12 13 1 1
21 22 23 2 2
31 32 33 3 3
C d
C d
C d
γ γ γ    
    γ γ γ =    
    γ γ γ    
    (38) 
where: 
 
( 1)
1
( 1) ( )1
2
2
3
131, 1, 1
( ) 1 1, ,3,
D t D t D tj j j
j j j
j i j
e e e
d t j
− − −γ = − γ = − γ = −
=µ …= −
   (39) 
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Replacing A with C,  β with γ and b with d in Equations (28)-(30) yields the closed form 
solution to C1, C2, C3 in Equation (38). 
 
Given ( )i tµ  in Equation (34), the analytical solution to Equations (10) and (11) after 1 
minute based on the integrating factor can be approximated by: 
 
( ), ,1( ) (1) int ( )( )i approx b approx i ii
I t I u t
t µµ
= +                     (40) 
( ) ( ) ( )1 2 33 31 1 2 20
1 2 3
int ( ) ( 1) D t DD t D D t Di
B B Bt t B e e e e e e
D D Dµ
= − + − + − + −  (41) 
 
where Equation (41) is derived from integrating Equation (34) from t=1 to t. 
 
2.4.3 Iterative solution 
 
For a given initial insulin approximation 0( )II tα =  from Equations (7)-(9), which 
corresponds to no saturation, Equations (20), (21) and (40) give an approximation to the 
solution of Equation (3) with saturation. This approximation can then be improved by 
replacing Iapprox(t) in Equation (11) with the piece-wise linear approximation of insulin in 
the first minute given by Equations (20), (21) and replacing Iapprox(t) by Equation (40) 
after 1 minute. Equations (20), (21) and (40) will then define a new approximation which 
can again be substituted into Equation (11) and so on. In practice this process could be 
continued until the relative percentage change is less than a tolerance. However, 
simulations over all physiological ranges of parameters show that only 2 iterations are 
necessary. Therefore the algorithm is summarised with 2 iterations as shown in Figure 1. 
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Step 1:  Define parameters n, αI, I0, ui, ub. Set parameters t1,t2,t3 which are used in  
              Equations (27) and (36).  
 
Step 2:  Evaluate ( )0.(0), , (1)5b b bII I from Equation (9), and 0 1 0 2 ( ), ( ),I It tI Iα = α =  
    0 3( )II tα = from Equations (7) and (8). 
 
Step 3: Evaluate ( )0.(0), , (1)5b b bα α α from Equation (12), and αi(1), αi(t1), αi(t2), αi(t3)  
 from Equation (22) 
 
 
Step 4: Evaluate Ib,approx(0.5) and Ib,approx(1) using Equations (17)-(21). 
 
 
Step 5: Evaluate β from Equation (27), A1, A2, A3 from Equations (28)-(30) and thus a0, a1,   
             a2, a3 from Equation (25) 
 
 
Step 6: Evaluate 1int ( )i tα , 2int ( )i tα , 3int ( )i tα  from Equations (32) and (33), D1, D2, D3,  
from Equation (36), )( 1tiµ , )( 2tiµ , )( 3tiµ  from Equation (31) and γ  from Equation  
(39). In Equations (28)-(30), replace A with C, β with γ and b with d to obtain C1,  
C2, C3 which will solve Equation (38) 
 
Step 7: Calculate B0, B1, B2, B3 from Equation (37), and thus compute Ii,approx(t1),  
 Ii,approx(t2), Ii,approx(t3) from Equations (40) and (41). 
 
 
Step 8: Start again at Step 3 but replace Ib(0.5), Ib(1) with Ib,approx(0.5), Ib,approx(1) in Step 4  
 and replace 0 1 0 2 ( ), ( ),I It tI Iα = α =  0 3( )II tα =  with Ii,approx(t1), Ii,approx(t2),  
 Ii,approx(t3) in Step 7. Repeat Steps 3-7 
 
Step 9: Output the new updates to , ,(0.5), (1),b approx b approxII Ii,approx(t1), Ii,approx(t2), Ii,approx(t3) 
  which characterize the main features of the solution to Equation (3) 
 
 
Figure 1: Algorithm for solving Equation (3) for insulin I(t) 
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2.5 Analytical Solution Q(t)  
 
Given the discrete function evaluation, Ib,approx(1), Ii,approx(t1), Ii,approx(t2), Ii,approx(t3) from 
the algorithm of Figure 1, the continuous solution Ii,approx(t) over the whole time period is 
first approximated by: 
 
0
2
, 1 2 3( ) ( )
nt
i approx a a a aI t t t e−= + + +    (42) 
where: 
 
1 2 30 0 1 2 3, , , , , ,a a a a a a a a≡ in Equation (25) with (1)iα replaced , (1)b approxI    
1 2 3, ,AA A ≡ Equations (28)-(30) with , ,) (1), 1, ,3(j i approx j b approxI I jb t= − = …  (43) 
 
For generality, Equation (4) is rewritten in the form: 
 
2 ( ) ( )Q k Q t kI t= − +      (44) 
 
where k2 = k in this case. 
 
To approximate the solution Q(t) of Equation (44), I(t) is defined: 
 
0 , 0
,
( ) ( (1) ) , 0 1
( ), 1 60i approx
b approx tI t I I I t
I t t
≤ ≤
= ≤
=
≤
+ −
   (45) 
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where I0 is the given initial condition of I(t) at t=0. With Equation (45) and 20 1 3, , ,a a a a in 
Equation (43), Equation (44) can be readily solved for Q(t) in Maple which yields: 
 
( 1)
2 1 2( ) ( ) ( (1) (1)) , 1
k tQ t Q t Q Q e t− −+ − ≥=    (46) 
0 1 2 32 1 2 3
2
( ) ( ) ( ) ( )a a a
kQ t C t C t Ca a a at
k
= + + +         (47) 
2 2
1 0 , 2 0 0 2 ,2
2
(1) ( (1)( 1) ( ( 1) (1)) )k kb approx b approx
kQ Q e I k I I k I e
k
− −= + − + − + −        (48) 
2 2
2 2 2
2 32 3
2 2 2
1
(( ) 1) (2 ( ) 2 ( )), ,
( ) ( )
nt nt
a a a
ntk k k n t k k n t t k nC e C e C e
k n k n k n
− − −− − + − − −= = =
− − −
  (49) 
 
Setting 2k k= in Equations (47)-(49) gives an approximation of the solution to ( )Q t in 
Equation (2). 
 
2.6 Glucose solution at 60 minutes 
 
Equation (5) is first re-written in the form: 
 
0 1( )
k t
total to
p
talG Q t G d d e
−+ = +    (50) 
where: 
 
                        0 11 1
( )( ) , , (0)
1 ( )G I G
Q tQ t p S d d P
Q t
P P= + = = −
+ α
   
1 new feed rate, (0) old feed rateP P≡ ≡                                               (51) 
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( )Q t is defined in Equations (46)-(49)             
 
 
The integrating factor of Equation (49) is defined: 
 
( )
0( )
tQ t dt
G t e
∫µ =      (52) 
 
The interstitial compartment of Equation (2) essentially acts like a low pass filter, so that 
the sharp peak insulin response I(t) in the blood plasma is significantly smoothed out. 
Thus, compared to ( )I t in Equation (45), a much simpler approximation of )(tQ can be 
defined: 
 
2 3
1 2
4
(0)
ˆˆ ˆ( )
ˆ1approx
Q a tt a t a t
a t
Q= + + +
+
   (53) 
 
where the nonlinear term is added to approximately account for saturation. Note that a 
pure quartic was found to be not suitable for Equation (53) as it had significant 
oscillations. Higher order approximations had similar problems, and require 20+ 
evaluations of ( )Q t and least squares to ensure a robust solution. Hence, the form of 
approximation in Equation (53) is important for minimizing computational cost and 
represents the most minimal model that gave satisfactory results. 
 
For a given choice of 1 2 3 4ˆ ˆ ˆ ˆ, , ,t t t t , define the values: 
1 1 2 2 30 3 4 4ˆ ˆ ˆ ˆ(0), ( ), ( ), ( ), ( )Q Q Q Q t Q Q t Q Q t Q Q t= = = = =     
where ( ) Q t ≡Equation (51)            (54) 
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Setting ˆ( ) ,approx j jQ Qt = 4,...,1=j yields four equations which can be readily solved in 
Maple for 1 2 3 4ˆ ˆ ˆ ˆ, , ,a a a a . The solution is: 
 
1 2 3 41 2 3 4
4
1 2 3 41 2 3 4
2 4 1 1 4 1 2 4
00
0 1 31 2 3
4
3 4 1 4 2 1 2 21 2
4
3
1 2
0
1
0
0
0 1
1
ˆ
1 ˆ ˆ ˆˆ ˆ ˆ ˆ( (1 ) (1 ) (1 ) )
ˆ
1 ˆ ˆˆ ˆ(1 )(1 )( )
ˆ
ˆ1ˆ ˆ(
ˆ
ˆ
1
ˆ
ˆ ˆ)
Q Q Q Q Q
Q Q Q Q
Q Q Q Q
Q Q Q
Q Q Q Q Q
Q Q Q Q
Q Q Q
a a a a a
a
b b b b
a C C a t C a t C a t
a
Q
a a Q Q Q
Q Q
a t t d d d a
a
aa t a
t
+ + + +
=
+ + +
= + + + + + +
−
= + + + + −
= − − −
+ 1 4ˆt a
 (55) 
34 14 13 24 23 210
2 3 4 34 24 23 1 3 4 34 14 131 2
1 2 4 14 24 21 1 2 3 13 23 213 4
1 2 31 1 2 2 3 3
ˆ ˆ ˆ ˆ ˆ ˆ ˆ ˆ ˆ, ( ), ( , ) {1,2,3,4}
ˆ ˆ ˆ ˆ ˆ ˆ ˆ ˆ ˆ ˆ ˆ ˆ,
ˆ ˆ ˆ ˆ ˆ ˆ ˆ ˆ ˆ ˆ ˆ ˆ,
ˆ ˆ ˆ, , ,
ij i jQ
Q Q
Q Q
Q Q Q Q Q Q
a t t t t t t t t t i j
a t t t t t t a t t t t t t
a t t t t t t a t t t t t t
b t a b t a b t a b
= = −
= − =
= = −
= − = −
∈
= − 44 4
ˆ
Q Qt a= −
  (56) 
 
0 1 21 2 3 1 13 21 2 23 21
3 0 1 23 13 23 1 2 1 21 2 21
1 1 1, ,ˆ ˆ ˆ ˆ ˆ ˆ ˆ ˆ ˆ
1 1 1 1, , ,ˆ ˆ ˆ ˆ ˆ ˆ ˆ ˆ ˆ
Q Q Q
Q Q Q Q
C C C
t t t t t t t t t
C d d d
t t t t t t t t t
− − −
= = =
−
= = = =
  (57) 
 
where Equations (55) are written in recursive form for computational efficiency. An 
approximation to Equation (52) is thus defined: 
 
ˆ1 1 12 3 3ˆ ˆ ˆ(0) ln(1 )1 2 4ˆ ˆ2 3 4 4( )
at a t a t t a t
a a
G
Q
t e
+ + +
 
 

− +
µ =    (58) 
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A similar approach to Equations (34)-(39) could be used to create an integrable 
approximation to )(tGµ . However, the values of SI in Equation (51) are typically on the 
order of 510−  [20], thus )(tGµ increases at a significantly lower rate than )(tiµ in Equation 
(31). Thus, it is possible to accurately represent )(tGµ of Equation (58) by a low order 
polynomial to reduce computation. A cubic is chosen, which is defined: 
 
2 3
0 1 2 3
ˆ ˆ ˆ(ˆ ˆ)G t b b t b t b t= + + +µ      (59) 
2 3 41 2 3 4
0 1
3 2 3 3
3 2 3 2 2 3
2 1
2 3
2
2
1,
2
1 2 2
3 3
2
,
2
ˆ ˆ1,
ˆ ˆ ˆ ˆ1 1ˆ ˆ
ˆ ˆ
ˆ ˆˆ ˆ(1 )ˆ
ˆ
ˆ
ˆ
denom
denom
a a a a
b b
t t t tb b
t t
t b t bb
t
b
b
µ µ µ µ+ µ + µ + µ= =
− − µ + µ
= − + +
 
 
+ −µ

−
=

+
   (60) 
 
2 2
24 34 2 3 3 4 2 4 32 3 4 34 2 4 241 2 3
2 2
2 3 32 1, 2 3 4 34 2
2
4 3 2, 2
2 3 3
34
4
3
4
2
ˆ ˆ ˆ ˆ ˆ ˆ ˆ ˆ ˆ ˆ ˆ ˆ ˆ ˆ
( )
ˆ( ) , ( ) , ( )
ˆ ˆˆ ˆ ˆ
, ( ),
ˆ ˆ ˆ ˆ ˆ ˆ ˆ ˆ ˆ( ) )
)
, ,
(
(denom deno
G G G
m
a t t t t t t t t t a t t t a t t t
t t t
a t t t b t t t t t t b t t t
µ µ µ
µ
= −
µ = µ µ = µ µ
+ + = −
= µ
=
= = =     (61) 
 
where ijtˆ is defined in Equation (56), ( )G tµ is defined in Equation (58), 321 ˆ,ˆ,ˆ bbb  are 
chosen so that ) )ˆ(ˆ (ˆ jG G jt t= µµ , j=2,..,4 and 2 3 4ˆ ˆ ˆ, ,t t t are the same ponts in Equations (55)-
(57). Note that since 0ˆ 1b = in Equation (59), only the three time points 2 3ˆ ˆ,t t and 4ˆt are 
required to uniquely determine 321 ˆ,ˆ,ˆ bbb . Putting 4ˆt =60, and solving Equation (50) by the 
integrating factor, gives the final solution for glucose at 60 minutes, which is defined: 
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1(60) ( (0) int (60))
(60)total totalG G
G G µ= +µ
   (62) 
( )2 3 4 ˆ ˆ ˆ ˆ0 4 4 1 4 2 4 3 1 1 2 30 1 2 31 1 1ˆ ˆ ˆ ˆ ˆ ˆˆ ˆ ˆ ˆint (60) 2 3 4G b b b bd t t b t b t b d C C b C b C bµ
 
 = + + + +

+

+ +   (63) 
( ) ( )( )
( )( )
( )( )
ˆ ˆ4 4
ˆ ˆ 42
ˆ2 2
0 1
32
43
4
ˆ 4 4
ˆ3 3 2 2 4
ˆ 4 4 4
1 1 ˆ1 , 1 1
ˆ ˆ2 2
ˆ ˆ
1 2
1 36 66 ˆ
k t k tp p
pb b
p p
k tp
p pb
p
k tp
p p pb
p
e k t e
k k
k t k t e
k
k t k t k t
k
C
e
C
C
C
− −
−
−
− ==
+
− +
= − +
= − ++ +
          (64) 
 
 
 
2.7 Adaptive choice of time points 
 
The time points 1 2,t t in Equation (27) and (39) and 1 2 3ˆ ˆ, ˆ,t t t in Equations (55)-(61) need to 
be chosen carefully to maximize accuracy. 
 
2.7.1 Choice of 1 2,t t in Equation (27) and (39) 
 
The time points 1 2,t t in Equation (27) and (39) are associated with the decay in the insulin 
curve ( )I t . The key determinant of this decay is the insulin clearance parameter n in 
Equation (3). The insulin saturation Iα , and the exogenous insulin input ( )exu t from 
Equation (6) do not significantly change the rate of decay. To enable an analytical 
determination of the time points 1t and 2t , Iα and the parameters bu and iu in Equation (6)  
are defined: 
 
2000ˆ ˆ0, 3000 mU/min, mU/min
60I b i
u uα = = =   (65) 
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An approximation to the insulin decay is thus defined: 
 
ˆ ( )iI t ≡Equations (7)-(9), with parameters defined in Equation (65)  (66) 
 
The steady state value of ˆ ( )iI t in Equation (66) is given by: 
 
,
ˆˆ i
i ss
uI
n
=      (67) 
 
The two time points 1t and 2t are defined: 
 
20% 2%
1 2
1 1
ˆ ˆ1 11 ln , 1 lnˆ ˆ
i i
i i
u I u It
n I
t
u unI
n n   − −
= − = −   − −   
   (68) 
1
10ˆ nb i b iu u u nI e
n n
u−+ + − = −  
 
   (69) 
( ) ( )20% , 1 , 2% , 1 ,1 1ˆ ˆ ˆ ˆ ˆ ˆ ˆ ˆ,5 50i ss i ss i ss i ssI I I I I I I I−= − +=+   (70) 
 
where: 
 
2 2%21 0%,ˆ ˆ ˆ ˆ( ) ( )I t I I t I= =     (71) 
 
and 20%Iˆ (or 2%Iˆ ) represent 20% (or 2%) of the difference from the steady state value 
,iˆ ssI to the peak value 1ˆI . The value of 2% was chosen since the resulting value 
of 2t corresponds quite closely to the maximum curvature in ˆ( )I t , after which the curve 
rapidly approaches a horizontal line. The value of 20% was chosen as it corresponds to 
about 1.5 time constants, which occurs approximately at the point where ˆ( )I t starts 
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moving away from its initial linear decay. Simulation has also confirmed that these 
values are optimal choices over all physiological ranges of the parameters.  
 
The major advantage of the choice of 1t and 2t in Equations (68), is that they automatically 
account for differences in the clearance parameter n which can change significantly 
between patients [30]. Thus, the approximation of Equation (42) is essentially 
independent of the clearance n , ensuring a robust and accurate solution, that can adapt to 
different patients.  
 
2.7.2 Choice of 1 2 3ˆ ˆ, ˆ,t t t in Equation (56) 
 
The time points 1 2 3ˆ ˆ, ˆ,t t t in Equation (56) are associated with the rise and decay of the 
interstitial insulin ( )Q t . The key feature in ( )Q t which can change significantly between 
patients is the time of the peak. This peak time is affected by both the clearance n and the 
effective insulin life parameter k in Equations (2) and (3). Solving Equation (3) for 
0( 1),Q t t≤ ≤ , with a linear insulin approximation ˆ ˆ ˆ(0)( ( (1) (0 )) )i i iI I II t t+ −= , and 
with ˆ ( )iI t given in Equation (66), yields an approximation to (1)Q defined: 
 
( )0(1) (0)1ˆ ˆ ˆ ˆ ˆ(1) ( (1 ) (0) ( )( 1) 1)i i i ikQ e I k I kQ I k Ik
−= − + + + + −           (72) 
 
In Maple, solving Equations (2) and (3) for ( , 1)Q t t ≥ , with the parameters in Equation 
(65), then solving ( ) 0Q t =  for t, yields an approximation to the ( )Q t peak time: 
 
1 1
max
1
ˆ1 ( )ˆ ln 1
ˆ
i
i
k n Q u kIt
k n u I n
 − + −
= + − − 
  (73) 
 
The three time points 1 2 3ˆ ˆ, ˆ,t t t in Equation (56) are equally spaced around maxtˆ which 
yields: 
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max
max
max
1 2 3,
ˆ ˆ 60ˆ ˆ ˆ ˆ,
2 2
t tt t t t += = =     (74) 
The approximation in Equation (74) accounts for significant shifts in the peak time 
of ( )Q t due to changes in n and k. Thus, the approximation in Equation (53) automatically 
adapts to different parameters ensuring a robust and consistent solution to ( )Q t . 
 
2.8 Summary of algorithm 
 
The following flow chart in Figure 2 summarises each step of the analytical algorithm 
which solves Equations (2)-(5) for each insulin and feed input on the hour. 
 
 
 
 
Figure 2: Algorithm for approximate analytical solution of Equations (2)-(5). 
Input Parameters: 
( )0I , ( )0Q , ( )0G , IS , GP , ( )exu t , n , k , pk , ( )0P  and ( )0P , where ( )0I , ( )0Q , ( )0G  
are set equal to ( )60I , ( )60Q , ( )60G  from the prior hour. 
  
Compute 1 2,t t from Equations (68)-(71), and calculate , ,(0.5), (1)b approx b approxII , 
and , 1 , 2 , 3( ), ( ), ( )i approx i approx i approxt II t I t from the algorithm in Figure 1. 
 
Compute 2 31ˆ ˆ ˆ, ,t t t from Equation (74) and set 4ˆ 60t = . Compute 20 1 3, , ,a a a a  from 
Equation (43), { }ˆ( ), 1, ,3, 1, ,4jia i jC t = … = …  from Equation (49), 1(ˆ )Q t , 2ˆ( )Q t , 
3ˆ( )Q t , 4(ˆ )Q t from Equation (46) and 1 2 3 40 , , ,,Q Q Q Q Q from Equation (54). 
Output (60)totalG from Equation (62), , 3(60) ( )i approxI I t= and (60)Q   
Compute 2 41 3ˆ ˆ ˆ ˆ, , ,a a a a from Equations (55)-(57), 2 3 4, ,µ µ µ from Equations (61) and 
(58), and 1 30 2, ,ˆ ˆ ˆ , ˆb b b b from Equations (60) and (61). 
 
Compute ˆ (60)Gµ from Equations (59)-(61) and 0nt )i (6Gµ from Equations (63) 
and (64) 
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The algorithm of Figure 2 is applied every hour in this study, to produce the glucose 
response from a given insulin bolus and/or infusion, nutritional infusion and identified 
insulin sensitivity for that hour. The parameters n and k are assumed constant for a given 
patient. Hence, a number of variables in the algorithm of Figure 2 can be pre-computed 
before the full simulation from hour to hour to reduce computation. These pre-computed 
variables are summarized: 
 
• Pre-compute 1 2,t t from Equations (68)-(71), β from Equation (27) and A1, A2, A3 
from Equations (28)-(30) 
• Pre-compute{ }(1), ( ), 1, ,3, 1, ,3i i jt i jφ φ = … = … from Equation (33), to allow fast 
computation of 1int ( )i tα , 2int ( )i tα , 3int ( )i tα from step 6 of Figure 1. 
• Pre-compute 
0 4 1 4
, , ,, ,Q Q Q Qaa b b… … from Equation (56) and 
0 3 0 2
,, , , ,Q Q Q QCC d d… … from Equation (57) 
• Pre-compute 1, 2,1 4
ˆ ˆ, ,, , denom denoma b baµ µ… from Equation (61) and 
{ }ˆ( ), 1, ,3, 1, ,4jia i jC t = … = …  from Equation (49) 
 
 
2.9 More general model 
 
The insulin Equations (2) and (3) are decoupled and can be solved independently to the 
glucose Equation (5). One physiological mechanism that can couple insulin to glucose is 
endogenous insulin production (EIP), which typically increases as blood glucose 
increases. In a type 2 diabetic this mechanism is still present, but is significantly less 
effective at controlling glucose [45]. 
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The infusion of insulin is known to suppress EIP [46], and in type 1 diabetes there is no 
EIP. In critical care insulin is continuously infused, and thus the model of Equations (2)-
(5) is appropriate in these cases. However, to allow the possibility of more complex 
models that account for EIP-glucose coupling which could occur in non-insulin 
dependent diabetes, or in cases where no insulin is present, a more general model is 
considered. This model is also presented to demonstrate that the methods developed in 
this paper are generalizable. The new model is defined: 
 
( )( ) ( )
1 ( )G e I G
Q tG p G G S G P t
Q t
= − − − +
+ α
      (75) 
2 3
( )( )
1
ext
I
nI u tI n I Q n G
I V
= − − − + +
+ α
    (76) 
( ) QQ k Q I k Q= − − −        (77) 
 
where ( )P t is defined in Equation (4). The form of Equations (75)-(77) is based loosely on 
the physiological model of [30], but in this case EIP is assumed to be proportional to 
glucose to create a glucose-insulin coupling. The purpose of this model is purely to test 
the methods, therefore, the physiological justification and interpretation of parameters is 
not given here, see [30] for more details. 
 
To allow the algorithm of Figure 2 to be used directly to solve Equations (75)-(77), the 
Equations of (76) and (77) are reformulated and approximated by: 
 
ˆ ˆ( ) ( )extI t I u t= −α +       (78) 
2 2, QQ k Q kI k k k= − + = +                                                    (79) 
  3 22ˆ ˆ( ) ( )1
( ) ( ), ext mean meanext
I
n u n Gt n u t t
I V
V n Q
α = + =
+
+ α
+              (80) 
   60 600 0
1 1( ) , ( )
60 60mean mean
G t dt Q Q tG dt= =∫ ∫                 (81) 
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where ( )extu t is defined in Equation (6), and meanG and meanQ  are constant approximations 
toG andQ  in Equation (76). Note that, the integrals of Equation (81) are approximated 
by the trapezium rule and are defined: 
0 0ˆ ˆ ˆ ˆ(60) ( ( )) (60 )( ( ) (60)),
2 120
total max max max max
mean mean
G G t Q Q t t Q t QG Q+ + + − += =    (82) 
where mˆaxt is defined in Equation (73). The algorithm for solving Equations (75), (78) and 
(79) is given in Figure 3. Note that more accurate higher order polynomial 
approximations to G andQ  in Equation (76) could be readily included by re-computing 
Equations (15), (20), (21) and Equations (40) and (41), using ˆ ( )extu t in Equation (80) 
rather than ( )extu t in Equation (6). All other equations would remain the same. However, 
it has been found in simulation that constant approximations to meanG and meanQ  are more 
than adequate for approximating the solution to Equations (75)-(77), with errors in 
glucose typically less than 0.4%. In addition, the main purpose of this section is to show 
the generalizable ability of the overall approach to other glucose-insulin systems, which 
the example of Equations (75)-(81) achieves. 
 
 
Step 1: Set 0meanG G= and 0meanQ Q= in Equation (80) 
 
Step 2: Solve Equations (75), (78) and (79) using the algorithm of Figure 2 with 
( )b tα and ( )i tα in Equations (12) and (22) replaced by ˆ ( )tα in Equation (80); iu in 
Equation (6) replaced by 3 2( )mean meanV n Qn G +  from Equation (80); 2k in Equation 
(44) replaced by 2k in Equation (79).  
 
Step 3: Output )( mˆaxQ t , (60)Q and (60)totalG from Step 2 
 
Step 4: Approximate meanG and meanQ in Equation (81) by Equation (82) 
 
Step 5:  Repeat Steps 2-4 until (60)totalG changes by less than a given tolerance 
 
 
 
Figure 3: Algorithm for solving (75), (78) and (79) 
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3 Results  
 
3.1 Uncontrolled virtual patients 
 
In the retrospective trial of 17 ICU patients in [20] the patients were effectively 
uncontrolled due to insulin being administered “ad-hoc” by clinical staff using their own 
discretion and experience. The insulin sensitivity profiles obtained thus represent highly 
dynamic changes in patient’s metabolic systems, with significantly large changes in 
glucose levels. These variations can be simulated by solving Equations (2)-(5), using the 
same insulin and nutrition inputs given by clinical staff, providing a virtual retrospective 
clinical trial. A virtual trial on uncontrolled patients thus provides a test of the flexibility 
and robustness of the analytical solution to capture highly variable physiological changes 
in patients, and to control them clinically.  
 
Figure 4 shows the numerical versus analytical simulation results overlaid for Patient 87 
from the ICU cohort of [20] using the recorded insulin infusion profile which contained 
no boluses. Also shown is the glucose measurement points with 7% error bars and the 
time-varying insulin sensitivity. The insulin sensitivity was found using the parameter 
identification method detailed in [20]. This method of identifying insulin sensitivity has 
been validated against the glucose clamp in clinical trials [30], hence the profile in Figure 
4 is a realistic representation of the variability in the patient’s physiology. For further 
details on the parameter identification method see [20]. The reference glucose curve in 
the upper panel of Figure 4 is generated by solving the full glucose model of Equations 
(2)-(5) for each hour with an insulin sensitivity given in the lower panel. The 
carbohydrate and insulin inputs were recorded by nursing staff [20] and also change 
every hour. Figure 4 shows that the model accurately captures the measured glucose 
values and the mean absolute relative percentage error between the glucose curves is 
0.036% with a 90th percentile of 0.056%. These values are well within measurement 
errors of 7-10% and less than 100x smaller. Thus, the numerical and analytical solutions 
are, clinically, effectively identical. 
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Note that the large oscillations in glucose are primarily caused by significant changes in 
patient condition which are reflected by the large changes in IS in the bottom panel of 
Figure 4. The problem is that IS changes before nursing staff realize so that when they 
react to it, IS can change again so they will over (or under) respond. For a full analysis of 
these effects and the variability that can occur in IS , insulin dosing and carbohydrates see 
[44]. 
 
 
 
Table 1 shows the statistics of the absolute relative percentage error between the 
numerical simulation and the analytical method described in this paper, for the entire 17 
patient cohort. All patients were simulated with two different interventions. First, with 
only constant infusion inputs of insulin over 1 hour periods, which were the actual 
infusions given by the clinical staff [20]. The second intervention used a random bolus 
insulin input each hour of between 0 and 6 U to further test the method. Simulations were 
Figure 4: Numerical and analytical simulations of patient 87 [22] 
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compared to a standard numerical differential equation solver in Matlab using the exact 
same inputs. The values of n and k were fixed at population values throughout so that the 
only parameters that varied were the time varying ( )IS t and ( )eG t , where ( )eG t is a 12 
hour moving average of the measured glucose [20]. The ranges of variability in these 
parameters have been validated on clinical data. Every patient has a different ( )IS t  
profile, for example Figure 4 gives the ( )IS t  profile using patient 87. For more details on 
how much IS can change for patients in an ICU, see [20]. 
 
Over the whole cohort, the mean absolute relative error was found to be very small in 
both cases, especially for the simulation receiving insulin through a constant infusion. 
The mean absolute relative error for the simulation with only bolus insulin input, was 
found to be slightly larger, which is due to the Michaelis Menten saturation term in 
Equation (3) affecting the insulin bolus input more than the constant infusion. However 
with a peak error of 0.09% at the 90th percentile the error is essentially negligible and a 
very small fraction of the typical measurement error. 
 
 
Patient Median (%) 90th percentile 
Total cohort  
Infusion only 
0.009 0.024 
Total cohort  
bolus only 
0.035 0.091 
 
A random assortment of individual patient results is shown in Tables 2 and 3 for either 
infusion or bolus control methods. Results for these individual patients are similar to the 
overall results in Table 1, with the errors for the infusion based case a factor of 3-4 times 
smaller than that of the bolus based case. 
 
 
 
 
Table 1: Statistics for absolute percentage error for uncontrolled 
patient virtual trials 
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Patient Median (%) 90th Percentile 
2 0.01 0.016 
4 0.009 0.022 
7 0.009 0.017 
12 0.018 0.061 
15 0.005 0.011 
 
 
 
Patient Median (%) 90th percentile 
2 0.028 0.073 
4 0.047 0.112 
7 0.027 0.037 
12 0.065 0.104 
15 0.023 0.082 
 
 
3.2 SPRINT trial patients 
 
These simulations are used to show that the methods can handle the significant variations 
in the input of insulin and nutrition regimes that occur with SPRINT and/or in the 
development of new improved protocols. The first test is to compare the accuracy of the 
analytical method retrospectively on a 51 patient SPRINT cohort [13, 14]. First, the a 
priori known ( )IS t  profiles, and insulin and nutrition inputs of the 51 patients are used to 
forward simulate Equations (2)-(5) using both the analytical and numerical methods to 
assess the accuracy of this method. These values pre-define the parameters in the hourly 
cycle of the algorithm of Figure 2. 
 
Table 4 shows the per patient relative absolute percentage error results between the two 
methods for a random selection of 5 patients. Similar results to the patients in the 17 
patient ICU cohort are obtained with very minimal errors. Table 5 shows the statistics for 
the entire 51 SPRINT patient cohort with all errors below 0.1%. 
Table 2: Absolute % error statistics of infusion based simulations 
Table 3: Absolute % error statistics of bolus based simulations 
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Patient 
Median 
(%) 
90th percentile 
2 0.025 0.038 
20 0.025 0.047 
35 0.048 0.073 
43 0.022 0.035 
46 0.057 0.086 
 
 
 
 
Patient Median (%) 90th percentile 
Total  
SPRINT cohort 
0.033 0.064 
 
 
 
3.3 Random changes of all parameters 
 
To further validate the method, all the parameters , , ,G Ik n α α are randomly changed 
within the documented physiological ranges in the literature [20]: 
 
0.02 0.28 , 0.001 0.0399 , 0.00050.0053 0.0086 . 0, 0 0 38G Ik nδ = + δ α = + δ α = += + δ      
(83) 
 
where δ is a uniform random variable between 0 and 1. 
 
The remaining parameters 0 0 0 0 1, , , , ,,e ISG PQ I G P are defined: 
Table 4: SPRINT patient percentage error versus numerical solution for 
selected patients. 
Table 5: SPRINT patient percentage error versus numerical solution for the 
whole cohort patients. 
  33 
 
(0) (0)8, (0) 15, 15, 8, 0.0005e IQ I G SG = = = = =    (84) 
 
Note that, Tables 1-5 show that significant changes in the parameters of Equation (84) 
have little effect on the accuracy of the analytical solution method presented, so the test 
in this section investigates the effects of changes in the remaining parameters. 1000 
monte carlo simulations were performed and the median error in the glucose value at 60 
minutes was 0.046% with a 90th percentile of 0.14%. Figure 5 plots a histogram of the 
errors which is significantly skewed to the right, and thus shows that the method is very 
robust and accurate over all physiological ranges of the parameters.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: A histogram of all % errors in the 1000 monte carlo simulations of the extended 
glucose-insulin model of Equations (75)-(77) 
 
 
 
3.4 Error analysis and computation speed 
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The speed of the algorithm was tested on a PC with a 2.4GHz Pentium 4 processor and 
2Gb of RAM. The original numerical simulation code used to develop the SPRINT 
protocol [13, 14] was first run using Matlab’s ode45 differential equation solver. The new 
analytical method was then run on the same machine. Both algorithms are implemented 
to simulate a patient hour cycle, given predefined parameters every cycle. The overheads 
for inputting the parameters and storing the hourly measurement data are thus effectively 
identical for both simulation methods. Thus, any the differences in the processor 
execution time (CPU time) between methods should be independent of the input/output 
overheads.  
 
The step size for Matlab’s ode45 was based on an error analysis using patient 87 in 
Figure 4 with the same random bolus inputs used in Table 3. The “true” solution was 
assumed to be the numerical solution with a very small maximum relative tolerance 
(using odeset in Matlab) of 1e-8. A large number of tolerances were used ranging from 
1e-6 to 0.001 and the 90th percentile error over the resulting glucose response relative to 
the true solution is plotted in Figures 6 (a) and (b).  
 
Figure 6 (a) 90th percentile error of true versus approximated glucose for patient 87 from 
Figure 4 with a range of error tolerances (b) A closer view of the error for an error 
tolerance less than 4.6e-5 with no clear trend in the oscillations 
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As can be seen in Figure 6, the error response is very noisy and doesn’t reliably settle to 
less than 0.1% error until the relative error tolerance is less than 0.5e-5. Hence a value of 
0.1e-5 was chosen to ensure the 90th percentile error is always less than 0.1%. From 
Tables 1-5, the analytical solution has a 90th percentile that is typically well less than 
0.1%. Hence choosing the relative error tolerance of 0.1e-5 in the numerical solver 
provides a fair comparison in speed between the methods. Note that the value of 1e-3 
which gives an error of 1% in Figure 6(a) is the default in Matlab and corresponds to 
solving the differential equation with no step-size condition specified. 
 
As a further contrast, instead of reducing the relative error tolerance until the errors are 
less than 0.1%, the maximum step size allowed in ode45 is reduced. Figure 7 shows the 
result for maximum step sizes less than 0.2 which is the value where the 90th percentile 
error is oscillating around 1%. The curve is still noisy but follows a clear predictable 
trend of less variation as the error decreases, compared to Figure 6 which has no 
consistent trend and so is not as reliable. This result suggests that limiting the maximum 
step size is a more robust and reliable way of ensuring the error stays consistently low as 
compared to the faster way of reducing the relative tolerance. The dramatic differences 
between the responses in Figures 6 and 7 demonstrate the problem in managing error 
with “black box” differential equation solvers. These solvers are designed to solve every 
problem and hence cannot by definition, take advantage of a specific application. The 
approach of limiting the maximum step size was used in designing the original SPRINT 
system [13, 14], and has been found to be the most reliable way in other applications with 
stiff systems [36]. Hence both methods of numerical error management are considered 
when comparing the CPU times versus the analytical method. To keep the error below the 
0.1% cut off, the maximum step size is chosen to be 0.019. 
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Figure 7: Plotting the maximum step size versus the 90th percentile error in simulations of 
patient 87 of Figure 4. A clear trend can be seen consisting of smaller oscillations as the 
maximum step size decreases 
 
 
Table 6 shows the CPU times for both simulation methods applied on the 51 SPRINT 
patient cohort. Note that the average time taken for a simulation over an hour is 6.25e-6 
seconds for the analytical method, compared to 0.035 and 0.9 seconds respectively for the 
numerical solver. The analytical simulation is thus significantly faster, by a factor of 5600 
for the relative tolerance method and a factor of 144000 for the maximum step method. 
Hence, for both cases, significant reductions in computational effort are made, enabling 
for more extensive virtual trials and Monte Carlo analyses. 
 
 
 
Method CPU time (s) [rel tol, max step] 
Factor speed increase 
[rel tol, max step] 
Numerical simulation [129, 3305] - 
Fast simulation 0.023 [5600,144000] 
 
 
Table 6: CPU times for both simulation methods on a 2.4GHz machine for 
the 51 SPRINT patient cohort 
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3.5        General glucose model 
 
The algorithm of Figure 3 is applied to solve Equations (75)-(77). The 
parameters , , , ,G G Ikp n α α are taken to be the same as used for the simulations of Tables 
1-5 and ,e IG S and the initial conditions are defined in Equation (84). In addition, a bolus 
and infusion of 1 unit are used respectively. The physiological values for the remaining 
parameters 2 3, , Qn n k are unknown, since the model of Equations (75)-(77) has not been 
clinically validated. Therefore, to provide a mathematical test of the concept, the values 
of 2n and Qk are chosen randomly in the same way as n and k in Equation (83) and 3n is 
defined as 3 0.1 1.4n = + δ , where δ is a uniform random number between 0 and 1. Steps 
2-4 in Figure 3 are performed twice in each case, as further iterations were found to not 
give any significant improvements. 
 
After 1000 monte carlo simulations, the median error for this example was 0.16 % with a 
90th percentile of 0.42%, and no values were greater than 0.5%. These errors are greater 
than those in Tables 1-5 and Figure 5, but this is expected since the analytical solution 
only solves Equations (75), (78) and (79) which is an approximation to Equations (75)-
(77). As stated in the formulation of this general model, more accurate approximations to 
G andQ  in Equation (76) could be used if required. However, errors are still significantly 
less than the expected measurement error of 7%, and the results demonstrate that the 
overall approach can be applied to more general glucose-insulin models.  
 
4 Discussion and Conclusions 
 
The concept of “Model-based Therapeutics” and the importance of fast forward 
simulation for enabling the rigorous testing of protocols were introduced in this paper. 
For a non-linear glucose-insulin model an analytical solution was created by exploiting 
structure and partial analytical solutions in a subset of the model, then using an iterative 
approach to create the final solution. Analytical and closed form solutions were always 
found at each stage, by writing non-integrable functions in terms of integrable function 
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approximations in physiological ranges. The function approximations were made over 
carefully chosen time points that adapt to significant changes in the patient parameters 
and thus maintaining a high degree of accuracy in the results. 
 
The key idea was to tailor the solutions to the specific application which was the rapid 
calculation of glucose values only on the hour, given insulin bolus, infusion and feed 
inputs. Current methods are numerical, which compute the glucose values at every small 
time step within the hour, dramatically slowing down simulation speed, and hindering the 
number of protocols that could be tested. The application specific approach allows 
parameters or parts of solutions that are unchanged for long periods, to be pre-stored 
further reducing computation. For example expressions involving the population insulin 
clearance parameters n and k can be separated from the analytical solution and thus 
calculated only once before a full monte-carlo analysis. This de-coupling of expressions 
from the solution cannot be done in the standard numerical approach as all parameters 
and values are needed at every time step. 
 
The analytical approach gave speed increases 5600-144000 times faster than the 
numerical based approach depending on the error management method used in the solver. 
Very accurate solutions were found with 90th percentile errors typically around 0.1-0.2% 
for all ranges of parameters within physiological constraints. The increased efficiency has 
had a significant impact on the ability to develop improved protocols, as turn around time 
has been massively improved and still only requires a simple programming language like 
Matlab. In addition, the methods developed in this paper are general and could be applied 
to any type of glucose-insulin model as demonstrated by the accurate results for a more 
complex differential equation model. This modelled coupled the glucose to insulin in the 
plasma and interstitial insulin compartments, and the developed algorithms were readily 
adapted to this situation. Future work will look at applying this concept to other areas of 
bio-medical engineering for example cardiac modelling [32-35] and insulin sensitivity 
testing [30, 39]. 
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